Philippines plans to sue Sanofi over dengue vaccine: minister

Alicia Farmer
Декабря 8, 2017

But for those not previously infected by the virus, more cases of severe disease could occur in the long term following vaccination, Sanofi said.

The Philippines intends to sue pharmaceutical giant Sanofi after authorities suspended its anti-dengue vaccine in response to the company warning the drug could lead to severe infections in some cases, the health secretary said on Thursday.

More than 730,000 children in the Philippines have received the vaccine, commonly known as Dengvaxia.

The Philippines was the 1st country in Asia to approve the vaccine for individuals aged 9 to 45 years old in December 2015.

However, Ng does not recommend the vaccine for those who have never been infected with dengue virus.

Almost 734,000 children aged nine and over in the Philippines have received one dose of the vaccine as part of a programme that cost 3.5 billion pesos (more than $80 million Cdn).

Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila on Monday but did not say why action was not taken after a World Health Organization report in mid-2016 that identified the risk the company was now flagging.

Sanofi would be liable if it is found to have withheld material information "that would have changed the outcome of all of these problems and the decision-makers in the Department of Health in the previous administration", said Duque.

Читайте также: State reps ring bell for Salvation Army

Public Health Minister Piyasakol Sakolsatayadorn also said the ministry has not actually focused on the use of a dengue vaccine as a key means of preventing the disease.

"To see even one additional severe dengue case among those who have never seen a dengue infection before, you would need to vaccinate 5,000 people where nine out of ten have seen infection before and one out of ten hasn't."

"And as always, we stand ready to work with the DOH to provide information to affected families, and to support the DOH's deliberations on the future of the dengue vaccination program", World Health Organization said.

"As far as we know, as far as we are made aware, there are no reported deaths that are related to dengue vaccination", said Ruby Dizon, medical director at Sanofi Pasteur Philippines.

Authorities are still in the process of reviewing information about the vaccine including the epidemiological data and assessing whether it will be cost-effective to make the vaccine a part of the country's standard immunisation package, said Dr Suwanchai Watthanayingcharoen, director-general of the Department of Disease Control (DDC).

Sanofi was not immediately available to comment on Duque's remarks.

"Sanofi is a responsible company that has acted according to Philippine laws and regulations for the supply and sale of the vaccine according to the approved label in the country", the company said in a statement emailed to AFP. Since then, over 700,000 children have been vaccinated with Dengvaxia vaccine.

A new analysis from six years of clinical data showed Dengvaxia vaccine provides persistent protective benefit against dengue fever in those who had prior infection.

При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.

Код для вставки в блог

Other reports by

Discuss This Article